A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Bortezomib (Primary) ; Tabalumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 10 Jun 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.